Home Cart Sign in  
Chemical Structure| 1858276-04-6 Chemical Structure| 1858276-04-6

Structure of Subasumstat
CAS No.: 1858276-04-6

Chemical Structure| 1858276-04-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-981 is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities.

Synonyms: TAK-981

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Subasumstat

CAS No. :1858276-04-6
Formula : C25H28ClN5O5S2
M.W : 578.10
SMILES Code : O=S(OC[C@@H]1[C@@H](O)C[C@H](NC2=NC=NC=C2C(C3=CC([C@@H]4NCCC5=C4C=C(Cl)C=C5)=C(C)S3)=O)C1)(N)=O
Synonyms :
TAK-981
MDL No. :MFCD32062692

Safety of Subasumstat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
OPM2 cells 250 nM 16 hours Subasumstat treatment induced DNA repair and apoptosis signaling pathways in OPM2 cells. PMC9979771
T cells from patients with chronic lymphocytic leukemia (CLL) 1 μM 18 hours To investigate the effect of TAK-981 on T cell activation, results showed that TAK-981 reduced the expression of SUMOylated proteins. PMC10525033
HL-60 cells 10 nM 24 hours TAK-981 significantly reduced SUMOylation levels in HL-60 cells and showed synergistic cytotoxicity with AZA. PMC10772526
U937 cells 10 nM 24 hours TAK-981 significantly reduced SUMOylation levels in U937 cells and showed synergistic cytotoxicity with AZA. PMC10772526
THP-1 cells 10 nM 24 hours TAK-981 significantly reduced SUMOylation levels in THP-1 cells and showed synergistic cytotoxicity with AZA. PMC10772526
WT iTreg cells 100 nM 24 hours To investigate the effect of TAK981 on iTreg cells. Results showed that TAK981 treatment upregulated IFNAR1 and IFN γ, and decreased the expression of NRP1. PMC9722544
MCL cell lines 50 and 100 nM 3 days Evaluate the effect of TAK-981 on MCL cell viability, showing significant reduction in viable cells in 7/8 cell lines PMC9277803
Primary MCL patient samples 50 and 100 nM 3 days Evaluate the effect of TAK-981 on primary MCL patient samples, showing significant reduction in viable cells in 4/5 samples PMC9277803
JJN3 cells 250 nM 3 days Subasumstat monotreatment significantly reduced the viability of JJN3 cells and showed synergy with the proteasome inhibitor CFZ. PMC9979771
Multiple KRAS-mutant human and mouse cancer cell lines 10 µM to 1.5 nM 72 hours To evaluate the sensitivity of TAK-981 to KRAS-mutant cancer cells, the results showed that nearly 70% of the cell lines were sensitive to TAK-981, with IC50 values less than 1 μM. PMC11238369

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice MCL xenograft models tail vein injection 7.5 mg/kg twice weekly, until the end of the experiment Evaluate the anti-tumor activity of TAK-981 in MCL xenograft models, showing significant extension in median survival of mice PMC9277803
C57BL/6J mice and CAnN.Cg-Foxn1nu/Crl-Crlj mice Immunocompetent and immunodeficient mouse models Intraperitoneal injection 25 mg/kg Twice a week, continuous treatment To evaluate the antitumor effect of TAK-981 in immunocompetent and immunodeficient mouse models, the results showed that TAK-981 significantly suppressed tumor growth, indicating that SUMOylation inhibition exhibited an immune-independent antitumor effect. PMC11238369
NOD-SCID-gammaIL2Rnull (NSG) mice Acute Myeloid Leukemia (AML) xenograft model Intravenous (IV) and intraperitoneal (IP) injection 15 mg/kg Once daily for 9 days The combination of TAK-981 and AZA significantly inhibited tumor progression in the AML xenograft model and extended mouse survival. PMC10772526
NOD.CB17/AlhnRj-PrkdcSCID/Rj mice Multiple myeloma xenograft models Intravenous 25 mg/kg Twice per week for 7 days Combination treatment of subasumstat and CFZ significantly inhibited tumor growth without observable side effects. PMC9979771
Mice Sepsis models (CLP and LPS endotoxemia) Subcutaneous injection 7.5 mg/kg Every 24 hours for 4 days TAK981 improved survival in mild polymicrobial peritonitis by enhancing innate immune responses and peritoneal bacterial clearance. TAK981 also increased early TNFα production but did not affect the resolution of inflammation. PMC10374847
Mice MC38 tumor model Intravenous injection 15 mg/kg Day 7 and Day 14 To investigate the effect of TAK981 on tumor growth and Treg cell status. Results showed that TAK981 significantly suppressed tumor growth and prolonged animal survival. The therapeutic efficacy of TAK981 was eliminated in mice lacking IFNAR1 on their Treg cells, suggesting that reactivation of the IFN1–IFNAR1 pathway in Treg cells contributes to the mechanism of action of TAK981. PMC9722544
Mice A20 B-cell lymphoma model Intravenous injection 7.5 mg/kg Days 1, 4, 7, and 11 To investigate the effect of TAK-981 on the A20 lymphoma model, results showed that TAK-981 delayed tumor growth. PMC10525033

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03648372 Neoplasms|Lymphoma|Hematologic... More >> Neoplasms Less << PHASE1|PHASE2 TERMINATED 2023-12-14 University of California San D... More >>iego Moores Cancer Center, La Jolla, California, 92093, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, 55101, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, 44106, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.73mL

0.35mL

0.17mL

8.65mL

1.73mL

0.86mL

17.30mL

3.46mL

1.73mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories